| Mitosis is not a key target of microtubule agents in patient tumors E Komlodi-Pasztor, D Sackett, J Wilkerson, T Fojo Nature reviews Clinical oncology 8 (4), 244-250, 2011 | 335 | 2011 |
| Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins MS Poruchynsky, E Komlodi-Pasztor, S Trostel, J Wilkerson, M Regairaz, ... Proceedings of the National Academy of Sciences 112 (5), 1571-1576, 2015 | 188 | 2015 |
| Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials M Burotto, EE Manasanch, J Wilkerson, T Fojo The oncologist 20 (4), 400-410, 2015 | 168 | 2015 |
| Identification of non–small cell lung cancer sensitive to systemic cancer therapies using radiomics L Dercle, M Fronheiser, L Lu, S Du, W Hayes, DK Leung, A Roy, ... Clinical Cancer Research 26 (9), 2151-2162, 2020 | 124 | 2020 |
| The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer C O'Sullivan, M Edgerly, M Velarde, J Wilkerson, AM Venkatesan, ... The Journal of Clinical Endocrinology & Metabolism 99 (4), 1291-1297, 2014 | 112 | 2014 |
| Colorectal cancer survival gains and novel treatment regimens: a systematic review and analysis I Jawed, J Wilkerson, V Prasad, AG Duffy, T Fojo JAMA oncology 1 (6), 787-795, 2015 | 89 | 2015 |
| MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor AR Chakraborty, RW Robey, VL Luchenko, Z Zhan, RL Piekarz, JP Gillet, ... Blood, The Journal of the American Society of Hematology 121 (20), 4115-4125, 2013 | 89 | 2013 |
| Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth WD Stein, J Wilkerson, ST Kim, X Huang, RJ Motzer, AT Fojo, SE Bates Clinical Cancer Research 18 (8), 2374-2381, 2012 | 73 | 2012 |
| Progression-free survival is simply a measure of a drug’s effect while administered and is not a surrogate for overall survival J Wilkerson, T Fojo The Cancer Journal 15 (5), 379-385, 2009 | 70 | 2009 |
| Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis J Wilkerson, K Abdallah, C Hugh-Jones, G Curt, M Rothenberg, ... The Lancet Oncology 18 (1), 143-154, 2017 | 59 | 2017 |
| Hazard ratios in cancer clinical trials—a primer KB Blagoev, J Wilkerson, T Fojo Nature reviews Clinical oncology 9 (3), 178-183, 2012 | 50 | 2012 |
| Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin VL Luchenko, T Litman, AR Chakraborty, A Heffner, C Devor, J Wilkerson, ... Molecular oncology 8 (8), 1379-1392, 2014 | 48 | 2014 |
| Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the … PR Massey, JS Okman, J Wilkerson, EW Cowen Supportive Care in Cancer 23, 1827-1835, 2015 | 39 | 2015 |
| Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies A Duffy, J Wilkerson, TF Greten Hepatology 57 (3), 1068-1077, 2013 | 36 | 2013 |
| Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma KB Blagoev, J Wilkerson, WD Stein, RJ Motzer, SE Bates, AT Fojo Cell Reports 3 (2), 277-281, 2013 | 36 | 2013 |
| Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes M Burotto, J Wilkerson, WD Stein, SE Bates, T Fojo Seminars in oncology 46 (1), 83-99, 2019 | 33 | 2019 |
| FMRP-dependent Mdm2 dephosphorylation is required for MEF2-induced synapse elimination NP Tsai, JR Wilkerson, W Guo, KM Huber Human molecular genetics 26 (2), 293-304, 2017 | 31 | 2017 |
| Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example M Burotto, J Wilkerson, W Stein, R Motzer, S Bates, T Fojo PLoS One 9 (5), e96316, 2014 | 31 | 2014 |
| Bevacizumab and breast cancer: the E2100 outlier T Fojo, J Wilkerson The lancet oncology 11 (12), 1117-1119, 2010 | 28 | 2010 |
| TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer LV Wood, A Fojo, BD Roberson, MSB Hughes, W Dahut, JL Gulley, ... Oncoimmunology 5 (8), e1197459, 2016 | 27 | 2016 |
